This summary provides basic information about Foundayo but does not include all information known about this medicine
Ensure the healthcare professional has experience in comprehensive medical screening, insurance support, and ongoing follow-ups to handle side effects
"These findings may inform shared decision making when considering GLP- 1 receptor agonist therapy and highlight the need for further evaluation of dermatological outcomes in future studies." The study involved a large number of people: 12,004 patients using GLP-1 drugs were compared to 15,221 using SGLT-2 inhibitors, with an additional 11,964 GLP-1 users compared to 11,233 using DPP-4 inhibitors
One study found that over 90% of GLP1 users failed to meet requirements for Vitamin D, potassium and choline (Spreckley 2026)
Amersi thinks patients can benefit from microdosing now, even without data to prove its efficacy, if they work with a doctor to carefully monitor their response
But our craving for sweetness in scent isnt new
